Mainz Biomed N.V. - MYNZ Net earnings per share (EPS TTM)

mainzbiomed.com (MYNZ) - corporate logo

Mainz Biomed N.V. (MYNZ) revenues are based on the implementation of ColoAlert analysis for the detection of colorectal tumors. The annual volatility of net income per share TTM visualizes market expectations, where 12.00 serves as the current metric level. High costs associated with the thermal transportation of biomaterials impact margins. However, the expansion of laboratories in the US and Europe confirms the growth potential of preventive diagnostics.

Mainz Biomed (MYNZ) - Net earnings per share for the last 12 months from 02/11/2024 to 03/11/2026

Mainz Biomed NV - analytical breakdowns and key metrics (MYNZ)

- share price and consensus valuation forecast:
Initial company analysis:MYNZ (Mainz Biomed NV)
Original product of Mainz Biomed

For Mainz Biomed N.V. (MYNZ), the EPS YoY (TTM) percentage growth history reflects the earnings per share dynamics over a rolling year. This metric measures the rate of change in net income, allowing for an assessment of the business's actual scaling pace. The high sensitivity of this metric reveals the risks of overpaying for the asset when buying at the peak of a trend. For this company, the indicator's volatility depends directly on costly FDA certification processes. Stable EPS growth will confirm the successful navigation of competition within the oncology diagnostics sector.